英国剑桥，中国上海，2020.12.01：dafabe888手机版登录（上海）有限公司与Horizon Discovery集团有限公司今日共同宣布，双方签署两项关于GS敲除CHO K1细胞株的商业化使用授权。

Horizon公司在构建工程细胞株中全球领先，其提供的谷氨酰胺转移酶稳定敲除（GS^-/-）的中国仓鼠卵巢细胞（CHO）K1细胞株表达平台，将在dafabe888手机版登录的抗体药临床前项目开发、客户和合作方生物治疗产品的临床开发和商业化生产、以及一体化解决方案中发挥重要作用。

“dafabe888手机版登录是一家国际领先的生物技术公司，他们在早期药物发现、临床申报、临床试验管理中有丰富的经验。dafabe888手机版登录拥有完整的创新抗体药物研发实验室，CHOSOURCE能够脱颖而出，为他们的生物治疗方法开发以及一体化解决方案提供帮助也是我们喜闻乐见的事情。”Horizon生物生产事业部全球负责人Jesús Zurdo表示，“Horizon致力于使用我们的表达平台，为各种规模的创新组织赋能，增加他们的生物治疗产出。目前我们已经为超过80个组织提供了CHOSOURCE，覆盖了非盈利组织、早期创业公司、临床阶段生物技术公司以及综合型药企，至少协助了8个生物制剂进展到临床研究阶段。”

dafabe888手机版登录CEO郎国竣博士表示：“Horizon的CHOSOURCE为抗体和其他重组蛋白的高表达稳定细胞株的开发提供了便利，可以获得更高的生物制剂的产量，其表现已经获得业界和监管机构的公认。这一稳健的平台将极大的助力我们开发抗体药物、诊断试剂和细胞治疗原料的生产用细胞株，也将助力于dafabe888手机版登录给广大客户和合作伙伴提供更强、更完善的从靶点到IND申报的一站式服务、项目孵化或合作开发。”

Horizon独有的GS^-/- CHO K1细胞株和表达工艺有很多成功的生物医药开发案例，不仅涵盖以研究目的为主的瞬时表达，也涵盖临床和商业生产用生物制剂的稳定细胞株的开发，其也在新型多特异性抗体或其它复杂结构的分子中得到了应用。Horizon授权 CHOSOURCE表达系统于制药公司、生物技术公司、生物仿制药公司和合同生产企业等多种类型的机构，广泛助力新药的研发进程。

更多关于Horizon CHO表达系统的信息：

https://horizondiscovery.com/en/navigation/chosource

更多关于Horizon公司信息，请联系：

Zyme Communications (贸易、区域化媒体)

Lorna Cuddon

Tel: +44 (0)7811 996 942

Email: lorna.cuddon@zymecommunications.com

更多关于dafabe888手机版登录有限公司的信息，请联系：

战略发展部

闫闰

Tel: +86 400 821 0776

Email: run.yan@sanyoubio.com 

关于Horizon Discovery公司

Horizon Discovery集团有限公司（LSE: HZD）(“Horizon”) 推动基因编辑和基因重构在全球生命科学领域的应用，为科研和治疗领域探索的科学家们赋能。

基于超过10年工程化细胞株的经验，Horizon可以提供无与伦比的工具和方案，帮助科学家们加深对基因功能的诠释、鉴别疾病的驱动基因、加速精准医疗的发展以及诊疗工作的进程；使在人源和其他哺乳动物细胞系上进行任意基因编辑、功能调控成为可能。

Horizon的客户覆盖了世界前沿的科研机构、国际药企和生物技术公司，也包括临床诊断实验室。洞察到这些机构面临的挑战，Horizon着眼于开发差异化的创新解决方案，助力精准医疗的发展。

Horizon总部设立在英国剑桥，分别在美国和日本设有办事处。Horizon集团在伦敦证券交易所的AIM市场以“HZD”代码交易。

关于Horizon的CHOSOURCE™平台

(horizondiscovery.com)

关于dafabe888手机版登录

dafabe888手机版登录是一家国际领先的、专注于创新抗体药物研究、开发和提供整体解决方案的生物高技术企业。

公司致力于打造国际领先的创新抗体药高质量、高通量、集成化研发及价值转化平台，构建治疗、研发和诊断类产品与服务的业务生态系统，协同全球生物制药、诊断及药物研发公司，打开人类疾病诊断和治疗的新局面。

成立5年以来，dafabe888手机版登录一直保持快速发展。截止2020年11月，公司有专业团队150多人，其中博士及硕士比例超过70%，团队拥有完整的创新药物研发及产业化经验。公司在“上海漕河泾国家高科技园区”建立了数千平方米、设施设备先进的创新抗体药物一体化研发实验室，拥有以系列超千亿噬菌体展示抗体库为代表的、涵盖创新抗体药物发现、抗体工程改造、体内外药效筛选、抗体药物成药性分析、生产用细胞株构建、生产工艺开发等10大功能模块和40多个核心技术平台。公司持续推出“品质最佳、速度最快、成本最低”的新技术、新产品、新服务和新解决方案。公司已和全球100多家制药公司、药物研发机构、诊断试剂产品开发公司建立了友好的业务合作关系。

卓越创新、追求梦想、奋力拼搏、造福病患！dafabe888手机版登录期待与广大客户和合作伙伴一道，共同构建长期协同成长生态圈，共建健康社会。

(sanyoubio.com)

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Cambridge, UK, and Shanghai, China, 01 December 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has granted two commercial licenses for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals Co., Ltd. (“Sanyou”), a leading biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments. Sanyou will use Horizon’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line for the development of pre-clinical antibody drug projects and to support the clinical development and commercialization of its customers’ human biotherapeutic products as well as offering the platform through its contract research services.

“Sanyou is a leading biotechnology company with extensive experience in early stage drug discovery, IND filing and clinical trial management. The Company has established an integrated innovative antibody drug R&D laboratory and we are pleased CHOSOURCE has been selected tosupport its biotherapeutic pipeline and contract research services offering,” commented Jesús Zurdo, Global Head Bioproduction Business Unit, Horizon Discovery. “Horizonis committed to supporting innovative organizations of all sizes to empower biotherapeutic production using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organizations, from non-for-profit and early stage startups to clinical stage biotechnology and large pharmaceutical companies, and helped enable at least 8 biotherapeutics expressed in these cells to progressinto clinical trials.”

Dr. David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd., said: “Horizon’s CHOSOURCE facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins, and is recognized in the industry and by regulators for high yield manufacturing. This robust platform will be key in enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products and cell therapy-related components, and allow us to provide a stronger one-stop solution to our clients with IND ready projects through our contract research services and pipeline-enriching collaborations.”

Horizon’s proprietary GS knockout CHO cell line and protocols have a successful track record in the discovery and development of biopharmaceuticals, from transient expression for research applications to the development of stable cell lines for clinical and commercial production of biotherapeutics, including novel multi-specific and complex molecular architectures. The Company licenses its CHOSOURCE expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations.

For further information on Horizon’s CHO expression system please visit: 

https://horizondiscovery.com/en/navigation/chosource 

For further information from Horizon Discovery Group plc, please contact:

Zyme Communications (Trade and Regional Media)

Lorna Cuddon

Tel: +44 (0)7811 996 942

Email: lorna.cuddon@zymecommunications.com

For further information from Sanyou Biopharmaceuticals Co., Ltd., please contact:

Strategic Development Department

Run Yan 

Tel: +86 400 821 0776

Email: run.yan@sanyoubio.com 

Horizon Discovery Group plc

Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.

Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.

The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

About Horizon's CHOSOURCE™ platform

Horizon’s proprietary CHOSOURCE™ platform, consisting of a GS knockout CHO K1 cell line combined with a dual promoter expression vector, is now established as an industry standard for host cell line development, facilitating cell line selection and optimization of costs and production processes. A comprehensive cell line history and a clear intellectual property position ensure freedom to operate in biotherapeutic production. Horizon’s robust CHO GS knockout host cell line provides an optimal expression system with an excellent performance record. 

(horizondiscovery.com)

 Sanyou Biopharmaceuticals Co., Ltd

Sanyou Biopharmaceuticals is a leading international High-tech biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments.

Sanyou is committed to building world-leading antibody drug discovery and development platforms of high-quality, high-throughput, integrated R&D and value transformation. Sanyou is dedicated in constructing a business ecosystem for therapeutic, R&D and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, R&D companies to open a new era forthe diagnosis and treatment of human diseases.

Since Sanyou’s founding five years ago, Sanyou has been growing rapidly. As of November 2020, Sanyou has a professional team of more than 150 employees, of which more than 70% hold a PhD or master degree, and this team is deeply experienced in R&D and industrialization of innovative drugs. Sanyou has established an integrated R&D laboratory of several thousands of squaremeters with advanced facilities in Caohejing Hi-Tech Park in Shanghai. Thelaboratory have 10 functional modules and more than 40 core technology platforms, led by a series of super-trillion phage display antibody libraries,and followed by a full range of essential R&D platforms for innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, pharmaceutical properties analysis, cell line construction, andprocess development. Sanyou continues to provide new technologies, newproducts, services and solutions of "best quality, fastest speed and lowest cost". Sanyou has established friendly business relationships withmore than 100 pharmaceutical companies, drug development organizations anddiagnostic product development companies around the world.

“Excellenceand innovation, pursuit of dreams, striving and evolving, for the benefit ofpatients”, holding these principles and beliefs, Sanyou looks forward toworking with our customers and partners to build a long-term synergistic growth ecosystem and a healthy society.

(sanyoubio.com)